Impact of Sedation Practices on Clinical Outcomes Among Mechanically Ventilated Children (ISPMVC)

September 9, 2026 updated by: Yasmine Ahmed Abdelrahman

Impact of Sedation Practices on Clinical Outcomes Among Mechanically Ventilated Pediatric Intensive Care Unit Patients

evaluate the impact of sedation adequacy on clinical outcomes in mechanically ventilated children admitted to the pediatric intensive care unit (PICU).

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

evaluate the impact of sedation adequacy on clinical outcomes in mechanically ventilated children admitted to the pediatric intensive care unit (PICU). Sedation is fundamental in the Paediatric Intensive Care Unit (PICU) for mechanically ventilated children, seeking to improve their clinical outcome, enhance ventilator synchronisation, and promote tolerance of invasive procedures. Achieving appropriate sedation is hard, since both under-sedation and over-sedation are linked to negative outcomes, including extended mechanical breathing, heightened risk of ventilator-associated pneumonia

Study Type

Observational

Enrollment (Estimated)

30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Children admitted to PICU requiring invasive mechanical ventilation (MV) ≥ 48 hours and received any form of sedation or analgesia during ventilation ≥ 48 hours.

Description

Inclusion Criteria:

  • Children admitted to PICU requiring invasive mechanical ventilation (MV) ≥ 48 hours and received any form of sedation or analgesia during ventilation ≥ 48 hours.

Exclusion Criteria:

- children ventilated after cardiac arrest

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
mechanically ventilated children admitted to the pediatric intensive care unit (PICU).

Children aged between 1 months and 18 years of age

• Children admitted to PICU requiring invasive mechanical ventilation (MV) ≥ 48 hours and received any form of sedation or analgesia during ventilation ≥ 48 hours. (e.g., midazolam 4 (loading dose 0.05-0.1 mg/kg IV and maintenance dose 0.03-0.12 mg/kg/hr IV), fentanyl (loading dose 1-2 mcg/kg IV over 10min and maintenance dose 1-4 mcg/kg/hr IV infusion), ketamine (loading dose 0.5-1 mg/kg IV and maintenance dose 0.1-0.5 mg/kg/hr), morphine (loading dose 0.05-0.1 mg/kg IV and maintenance dose 0.05-0.1 mg/kg IV)
Other: no need
no need

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The Richmond Agitation-Sedation Scale (RASS)
Time Frame: 1 year
is a validated 10-point clinical tool used in PICUs to assess patient alertness, agitation, and sedation depth in <20 seconds. In your sedation-outcome study, nurses score RASS every 4-8 hours to classify adequate sedation (target: RASS -2 to 0) vs. under-sedation (>0) or over-sedation (≤-3)
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Yasmine Ahmed Abdelrahman

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 1, 2026

Primary Completion (Estimated)

May 1, 2027

Study Completion (Estimated)

June 1, 2027

Study Registration Dates

First Submitted

September 9, 2026

First Submitted That Met QC Criteria

September 9, 2026

First Posted (Actual)

September 15, 2026

Study Record Updates

Last Update Posted (Actual)

September 15, 2026

Last Update Submitted That Met QC Criteria

September 9, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • Soh-Med-26-6-11MS

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe